Key facts
- This page summarizes Glenn A. Eisenberg's Form 4 filing for LABORATORY CORP OF AMERICA HOLDINGS (LH).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 May 2024, 12:45.
Glenn A. Eisenberg - 30 Apr 2024 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)
- Reporting relationship
- Chief Financial Officer, EVP
- Issuer ticker
- LH
- Reported as of
- 30 Apr 2024
- Net transaction value
- -$905,360
- SEC form
- 4
- Accepted by SEC
- 02 May 2024, 12:45:13 UTC
- Prior SEC filing
- 17 Apr 2024
- Next SEC filing
- 15 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sandra D. van der Vaart, Attorney-in-Fact for Glenn A. Eisenberg
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Glenn A. Eisenberg filed Form 4 for LABORATORY CORP OF AMERICA HOLDINGS (LH) on 02 May 2024.
Change
- Previous filing in this sequence was filed on 17 Apr 2024.
- Current net transaction value: -$905,360.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LH
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +10,229
- Change %
- +25%
- Price
- Shares after
- 50,785
- Date
- 30 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
LH
transaction
Common Stock
Tax liability
- Transaction value
- $905,360
- Shares
- -4,496
- Change %
- -8.9%
- Price
- $201.37
- Shares after
- 46,289
- Date
- 30 Apr 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LH
transaction
Derivative
Performance Share Unit
Options Exercise
- Transaction value
- Shares
- -10,229
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 30 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,229
- Exercise price
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each Performance Share represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.
Footnote F2
Stock withholding to satisfy tax withholding obligations.
Footnote F3
Amount includes an additional 1,059 Performance Shares resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea Holdings Inc. ("Fortrea").
Footnote F4
The Performance Shares vested in full upon the filing of the Company's Quarterly Report on Form 10-Q for the first quarter of 2024, subject to both continued service and satisfaction of a performance condition related to the spin-off of Fortrea.